Value proposition

Transforming psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.

Beckley Psytech is a private, clinical-stage biotechnology company dedicated to improving the lives of people suffering from neuropsychiatric disorders by transforming psychedelics into effective and rapid-acting medicines.

Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients living with depression and other profoundly debilitating neuropsychiatric conditions with a high unmet need.

Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, we combine world-leading psychedelic science with deep neuropsychiatric drug development expertise in order to optimise patient outcomes, improve treatment and ease the burden these conditions have on individuals and society.

Psychedelic medicine, Pharmaceuticals, and Mental health